Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options

Published:2019-07 Issue:7 Volume:24 Page:1355-1369
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Meenakshi Sundaram Daniel Nisakar,Jiang Xiaoyan,Brandwein Joseph M.,Valencia-Serna Juliana,Remant K.C.,Uludağ Hasan^ORCID

Funder

Canadian Institutes of Health Research (CIHR)

Natural Sciences and Engineering Research Council of Canada (NSERC)

Edmonton Civic Employees

Women & Children Health Research Institute (WCHRI)

Hair Massacure Foundation

The Leukemia & Lymphoma Society of Canada

Alberta Innovates

CIHR

NSERC

WCHRI

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference156 articles.

1. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene;Ben-Neriah;Science,1986

2. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism;Sirard;Blood,1994

3. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner;Cambier;Oncogene,1998

4. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N. Engl. J. Med.,2006

5. Long-term outcomes of imatinib treatment for chronic myeloid leukemia;Hochhaus;N. Engl. J. Med.,2017

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia;Oncohematology;2024-09-01

2. Extracellular vesicle-mediated regulation of imatinib resistance in chronic myeloid leukemia via the miR-629-5p/SENP2/PI3K/AKT/mTOR axis;Hematology;2024-07-26

3. Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms;Frontiers in Pharmacology;2024-07-22

4. ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells;American Journal of Physiology-Cell Physiology;2024-07-01

5. S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia;OMICS: A Journal of Integrative Biology;2024-07-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3